Related Experiment Video
Updated: Jun 27, 2026
06:30
Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
Published on: May 23, 2025
Recent patents on ocular drug delivery systems
1Medicines Research Unit, School of Life and Health Sciences, Aston University, Aston Triangle, Birmingham, UK. B.R.Conway@aston.ac.uk
Recent Patents on Drug Delivery & Formulation
|December 17, 2008
Summary
This review examines patented ocular drug delivery systems for anterior and posterior eye segments. Innovations focus on sustained-release formulations to improve drug bioavailability and reduce dosing frequency.
Area of Science:
- Ophthalmology
- Pharmaceutics
- Biotechnology
Background:
- Ocular drug delivery faces challenges with drug bioavailability and penetration, especially for posterior segment diseases.
- Current methods include topical, systemic, and intraocular injections, with limitations in efficacy and patient compliance.
- Controlled delivery systems offer potential for improved ocular drug targeting and sustained release.
Purpose of the Study:
- To review recent patented advancements in ocular drug delivery systems.
- To highlight strategies for enhancing drug penetration and residence time in the eye.
- To discuss sustained-release systems for treating anterior and posterior segment ocular diseases.
Main Methods:
- Literature review of patented ocular drug delivery systems from March 2004 to present.
- Analysis of strategies for topical drug delivery, including enhanced penetration techniques.
- Examination of drug delivery systems for posterior segment diseases requiring sustained release.
Main Results:
- Recent patents showcase innovations in ocular inserts, minitablets, and disposable lenses for anterior segment delivery.
- Strategies like cyclodextrins, liposomes, and nanoparticles are explored to improve drug penetration.
- Development of sustained-release systems is driven by the need for less frequent dosing and less invasive treatments.
Conclusions:
- Patented ocular drug delivery systems are evolving towards enhanced bioavailability and targeted delivery.
- Innovations in controlled release formulations are crucial for managing chronic ocular conditions.
- Future directions emphasize less invasive and more effective therapeutic strategies for eye diseases.
Related Concept Videos
01:23Ophthalmic Drug Delivery Systems
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
01:22Drug Delivery: Miscellaneous Routes
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection, and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs through the...
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs through the...
01:19Modified-Release Drug Delivery Systems: Overview
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
01:11Oral Drug Delivery Systems: Delayed-Release Systems
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
01:23Modified-Release Drug Delivery Systems: Classification
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...